LEIDEN, NETHERLANDS -- (MARKET WIRE) -- October 30, 2006 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it will concentrate its research and development (R&D) activities at its Leiden headquarters in The Netherlands. Vaccine manufacturing, regulatory activities, clinical development and vaccine marketing will be concentrated in Crucell's Swiss operations in Bern.
